Short answer
Celcuity Inc. (CELC) filed an 8-K current report with the SEC on July 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). No substantive Regulation FD disclosure provided in the supplied excerpt.
Celcuity Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- No substantive Regulation FD disclosure provided in the supplied excerpt
- Text appears to be a filing-incorporation disclaimer, not investor-relevant operating information
Item 8.01 · Other Events
- Forward-looking disclosure centers on gedatolisib’s therapeutic potential, clinical trials, sNDA submission, and FDA review
- Commercialization timing and market opportunity remain contingent on regulatory approval and market acceptance
- Topline clinical results may change after comprehensive efficacy and safety data review
- Key risks include trial delays, competing therapies, and unfavorable access to capital
- Investors should treat management’s cash-use and balance-sheet expectations as subject to material uncertainty
Item EX-99.1 · Exhibit EX-99.1
- FDA approval makes REVTORPYK Celcuity’s first commercial product for HR+/HER2-, PIK3CA wild-type advanced breast cancer
- VIKTORIA-1 triplet reduced progression or death risk 76%, with median PFS 9.3 months versus 2.0 months
- Doublet reduced progression or death risk 67%, with median PFS 7.4 months versus 2.0 months
- Commercial launch targeted for late Q3 2026, creating near-term execution and market-access catalysts
- sNDA submission planned in Q3 2026 for PIK3CA-mutated disease, potentially expanding the eligible market beyond the initial indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celcuity Inc. 8-K filings
Get the next CELC 8-K as it lands
Follow CELC for push alerts, or ask the research agent what this filing means.